Heart failure & cardiomyopathies
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study
Authors' conclusion
Incorporating biomarkers based on the new HF guideline reclassified approximately 1 in 5 older adults without prevalent HF to Stage B.
Study context
- Population
- Older adults (mean age 75.8 years) without prevalent heart failure (HF) in the ARIC study
- Exposure
- Stage B HF defined with cardiac biomarkers vs Stage Anew
- Stage Bnewn = 4,326
- Stage Bbiomarkers onlyn = 1,123
- Outcome
- Incident HF and all-cause death
Methodological detailscommunity-based cohort (ARIC)
- Community-based cohort (ARIC)
Main finding
As reported in the abstract
Each group vs stage AnewHazard ratio (95% CI)
Stage Bnewincident HF
3.70(2.58–5.30)
Stage Bnewdeath
1.94(1.53–2.46)
Stage Becho+biomarkerincident HF; highest risk
6.34(4.37–9.19)
Stage Becho+biomarkerdeath; highest risk
2.53(1.98–3.23)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study. JACC Heart Fail. Published 1 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →